Live Biotherapeutics

Pfizer backing biotechnology innovation with $120m capital outlay

14-Jan-2021 By Jane Byrne

Pfizer is investing US$25m in a US developer of live biotherapeutics, Vedanta Biosciences; that project is one of four investments, totaling US$120m, made by Pfizer in the second half of 2020 under its breakthrough growth program focused on clinical stage...

US listing set to support and accelerate ongoing development of 4D Pharma’s live biotherapeutics

03-Nov-2020 By Jane Byrne

UK headquartered biotech, 4D Pharma, which is active in the live biotherapeutics space, is planning to move beyond AIM into the US NASDAQ.

Gilead agrees microbiome deal with Second Genome

07-Apr-2020 By Ben Hargreaves

Gilead announces partnership to identify microbiome biomarkers associated with a clinical response in compounds within its portfolio.

Microbiome therapies approaching ‘key inflection point’

21-Nov-2019 By Ben Hargreaves

After Finch Therapeutics extends partnership with Takeda, the biotech’s CEO outlines how next year could be a defining one for microbiome-based therapies.